Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorPerez Valderrama, B.
dc.contributor.authorCastellano Gauna, D.
dc.contributor.authorPinto Marin, A.
dc.contributor.authorMellado Gonzalez, B.
dc.contributor.authorPuente, J.
dc.contributor.authorCliment Duran, M. A.
dc.contributor.authorDomenech, M.
dc.contributor.authorVazquez Mazon, F. J.
dc.contributor.authorPerez Gracia, J. L.
dc.contributor.authorBonfill, T.
dc.contributor.authorMorales Barrera, R.
dc.contributor.authorBallester Navarro, I.
dc.contributor.authorGarcia del Muro, X.
dc.contributor.authorMaroto, P.
dc.contributor.authorJuan Vidal, O. J.
dc.contributor.authorRodriguez-Vida, A.
dc.contributor.authorBellmunt, J.
dc.contributor.authoraffiliation[Perez Valderrama, B.] Hosp Univ Virgen del Rocio, Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Castellano Gauna, D.] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Pinto Marin, A.] Hosp Univ La Paz, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Mellado Gonzalez, B.] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Oncol Serv, Barcelona, Spain
dc.contributor.authoraffiliation[Puente, J.] Hosp Clin Univ San Carlos, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Climent Duran, M. A.] Fdn Inst Valenciano Oncol, Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Domenech, M.] Fundacio Althaia Manresa, Med Oncol, Manresa, Spain
dc.contributor.authoraffiliation[Vazquez Mazon, F. J.] Hosp Gen Univ Elche, Med Oncol, Alicante, Spain
dc.contributor.authoraffiliation[Perez Gracia, J. L.] Clin Univ Navarra, Oncol, Salamanca, Spain
dc.contributor.authoraffiliation[Bonfill, T.] Parc Tauli Univ Hosp, Med Oncol, Sabadell, Spain
dc.contributor.authoraffiliation[Bonfill, T.] Parc Tauli Inst Res & Innovat I3PT, Sabadell, Spain
dc.contributor.authoraffiliation[Bonfill, T.] Barcelona Autonomous Univ, Sabadell, Spain
dc.contributor.authoraffiliation[Morales Barrera, R.] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Ballester Navarro, I.] Hosp Univ Morales Meseguer, Med Oncol, Murcia, Spain
dc.contributor.authoraffiliation[Garcia del Muro, X.] Inst Catala Oncol Hosp, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Maroto, P.] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Juan Vidal, O. J.] Pivotal SLU, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Rodriguez-Vida, A.] Hosp del Mar, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Bellmunt, J.] Harvard Med Sch, Dept Med Oncol, Boston, MA 02115 USA
dc.contributor.funderMerck AG
dc.contributor.funderPfizer
dc.date.accessioned2025-01-07T15:32:08Z
dc.date.available2025-01-07T15:32:08Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.2256
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420423385/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27216
dc.identifier.wosID573469102654
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS1158-S1159
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titlePhase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía